Specifically, interrupting CL-11 signaling or blocking its interaction with EGFR and TGF-β receptors could offer a novel strategy to suppress fibroblast proliferation and fibrogenic activity - providing a promising avenue for the treatment of renal fibrosis and potentially other fibroproliferative disorders. This evidence concerns the gene EGFR and renal fibrosis.